Matthew Moyle is a biopharma veteran with extensive experience in the discovery and development of novel therapeutic agents. He has led R&D groups at Boehringer Ingelheim, Amgen and Tanox, among others, resulting in the delivery of more than 20 drug candidates that have advanced to clinical testing, and the approval thus far of two products.
 

Prior to joining the Aravax team, Dr Moyle was Chief Scientific Officer at AnaptysBio. Dr Moyle received his BSc and PhD degrees in Biochemistry from the University of Toronto and completed postdoctoral studies at Genentech.